Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Prostate Cancer | Current Treatment: Physician Insights | US | 2023

Login to access report north_east
Contact sales account_box

Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant prostate cancer (mCRPC) market and account for sizable market shares in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. They compete with other next-generation hormonal therapies like Erleada (Janssen) and Nubeqa (Bayer HealthCare), two brands initially approved for nonmetastatic castrate-resistant prostate cancer (nmCRPC). The PSMA-targeted radioligand therapy Pluvicto (Novartis), which the FDA approved in March 2022, is having an impact on the treatment of mCRPC. The PARP inhibitors Lynparza (AstraZeneca) and Rubraca (Clovis Oncology) offer other biomarker-driven options for mCRPC treatment, and Xofigo (Bayer HealthCare) and Jevtana (Sanofi) are other nonhormonal treatment options for mCRPC, particularly in later lines.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant prostate cancer patient populations?
  • What is the uptake of the PSMA radioligand therapy Pluvicto in mCRPC to date?
  • What are the patient shares of key therapies in commercially relevant prostate cancer patient populations?
  • What are the main drivers of and obstacles to the uptake of current therapies in select hormone-sensitive and castrate-resistant patient segments?

Product Description

Current Treatment: Physician Insights provides physician insights ontreatment dynamics, prescribing behavior, and drivers of brand useso that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States

Primary research: Survey of 100 medical oncologists and urologists (50 of each specialty) in the United States fielded in May 2023.

Key drugs covered: Abiraterone, Xtandi, Erleada, Nubeqa, Orgovyx, Pluvicto, Provenge, Xofigo, Jevtana, Lynparza, Rubraca, others

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east